drugset / Trial / NCT00131378

Growth Hormone, Cardiovascular Risk, and Visceral Adiposity

NCT00131378 ↗

Completed 142 enrolled Massachusetts General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body composition will be measured.

Timeline

Start
2004-11
Primary completion
2012-11
Completion
2013-06

Outcome

Met primary endpoint

paper GH administration decreased TAT and hsCRP compared with placebo. PMID 22275471 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic — Subcutaneous

Indications